B. Riley initiated coverage of Koru Medical with a Buy rating and $4.50 price target. The company’s Freedom Infusion System delivers drug treatment under the skin, with a focus on the “growing” $500M subcutaneous immunoglobulin market for immunodeficiency diseases, while also transforming into a novel therapy delivery platform addressing a $2B-plus market opportunity, the analyst tells investors in a research note. The firm says the stock’s risk/reward is becoming more favorable with Koru’s domestic core market set to recover.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRMD:
- Koru Medical cuts FY23 revenue view to $31M-$32.5M from $32.5M-$33.5M
- Koru Medical reports Q2 EPS (5c), consensus (6c)
- Koru Medical price target lowered to $3.00 from $4.50 at Piper Sandler
- Koru Medical announces novel therapies collaboration in late-stage endocrinology
- Koru Medical submits FREEDOM60 510(k) premarket notification submission to FDA
